FDA accelerated approval for talquetamab-tgvs in multiple myeloma
The agency's approval, granted August 9, 2023, covers relapsed or refractory multiple myeloma patients under the brand name Talvey.
FDA
30 stories
The agency's approval, granted August 9, 2023, covers relapsed or refractory multiple myeloma patients under the brand name Talvey.
FDA
Rockwell Medical said the planned combination with Vantive's hemodialysis concentrates and machines business is projected to generate between $400 million and $450 million in annual revenue.
SEC filing
Opdivo is now approved for patients 12 and older with completely resected Stage IIB/C melanoma; a separate record lists a subcutaneous nivolumab-hyaluronidase approval with no details given.
FDA (3)
Zymeworks reported third-quarter 2026 results, raised full-year revenue and EBITDA guidance, and detailed a new Roche collaboration on ZW209 pending antitrust clearance.
SEC filing
The agency cleared capivasertib with abiraterone and prednisone for PTEN-deficient, androgen pathway modulation-naïve or -sensitive metastatic prostate cancer.
FDA (6)
The agency cleared Balversa for patients with locally advanced or metastatic urothelial carcinoma whose disease had progressed after prior therapy.
FDA
The agency cleared Inlexzo for a specific group of bladder cancer patients who did not respond to standard BCG therapy.
FDA
The approval covers adults with recurrent or metastatic HNSCC that progressed after platinum chemotherapy and an anti-PD-(L)1 antibody, based on tumor response data.
FDA press release, FDA, Drugs@FDA (10)
FDA approval of MIMRYLO triggered $275 million in payments to Protagonist, and the company plans a Phase 2b psoriasis study of PN-881 for early Q1 2027.
SEC filing
Contineum said its Phase 2 IPF trial of PIPE-791 now spans more than 100 sites in 16 countries, with cash runway projected through mid-2029.
SEC filing
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
Madrigal also outlined a new Phase 3 trial in well-compensated MASH cirrhosis and reported cash of $961.8 million as of Sept. 30, 2026.
SEC filing
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Merck reported $18.1 billion in third-quarter sales and detailed FDA approvals, a priority BLA filing for sac-TMT, and new guidance including one-time charges tied to the Cidara and Terns deals.
SEC filing (2)
The clearance paves the way for a planned U.S. Phase 1/2 study of the CD19/CD20 dual-targeting in vivo CAR-T therapy in relapsed or refractory B-cell malignancies.
SEC filing
The clinical-stage CNS drug developer moved its longtime scientific adviser onto the board as it pushes HLP003 through Phase 3 and HLP004 through Phase 2.
SEC filing
Johnson & Johnson posted 5.9% reported sales growth to $25.4 billion and raised its 2026 outlook, citing regulatory and clinical progress across its portfolio.
SEC filing
New Phase 1 lung cancer data, early CONVERGE efficacy signals, and a NANORAY-312 protocol amendment accompanied a first half 2026 financial report showing €110.9 million in cash.
SEC filing
JNJ-5120/PIPE-307, licensed to Johnson & Johnson, missed its primary efficacy measure in major depressive disorder, though the company reported no new safety signals.
SEC filing